A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

NCT02759107 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the medication tirzepatide in both healthy people and those with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 142 people

Who can join Ages 21–70 · all sexes Healthy volunteers accepted.

Timeline Started 2016-05 · est. completion 2017-06

Where 2 sites · Singapore, United States

What this study is testing ClinicalTrials.gov NCT02759107 ↗

Description as written by the study sponsor.

The main purposes of this study are to determine: * The safety of tirzepatide and any side effects that might be associated with it. * How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it. * How tirzepatide affects the levels of blood sugar. This study includes 3 parts (A, B and C). Part A involves a single dose of tirzepatide taken as a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in duration, including screening. Parts B and C involve 4 doses of tirzepatide taken once weekly (over 4 weeks) as a SC injection just under the skin and is approximately 12-14 weeks in duration, including screening. Each participant will enroll in only one part. This study is for research purposes only, and is not intended to treat any medical condition.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC
Dulaglutide also known as Trulicity® Drug

Administered SC

Main thing measured	Number of Participants With One or More Serious Adverse Event(s) (SAEs)
Sponsor	Eli Lilly and Company
Conditions studied	Healthy, Type 2 Diabetes Mellitus (T2DM)
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02759107 ↗